Roche Pegasys/Copegus Phase IV To Evaluate Higher Doses, Shorter Duration

Roche will conduct a pilot study to assess the safety and tolerability of higher doses of Pegasys and Copegus in hepatitis C patients with poor prognostic factors as part of its postmarketing commitments